文献速递多重用药老年慢病共病管理

老年糖尿病患者格列本脲使用趋势:区域医疗组织药房索赔数据分析

Glyburide Use in Older Adults: Pharmacy Claims Data Analysis of a Regional Healthcare Organization.
PubMed 文献 · J Am Geriatr Soc · 2020-08-05

该多中心回顾性队列研究分析2010至2015年四家Sharp Rees-Stealy诊所区域3005例65岁以上2型糖尿病患者的药房索赔数据,发现格列本脲使用率逐年下降(2011年35.8%、2013年27.7%、2015年4.2%,P<.01),2012年AGS Beers Criteria更新后使用率降低,但区域差异影响实施时机。

要点

  • 2012年AGS Beers Criteria发布后,老年2型糖尿病患者格列本脲使用率显著下降。
  • 格列本脲使用率2011年35.8%、2013年27.7%、2015年4.2%,各年度间P<.01。
  • 区域差异影响指南实施时机,2015年各区域间无显著差异。

核心结论

  • 2012年AGS Beers Criteria发布后格列本脲使用率下降,表明大型多区域机构成功采纳循证医学,但区域差异可能影响实施时机。

研究设计与样本

  • 多中心回顾性队列研究,比较四个Sharp Rees-Stealy诊所区域5年(2010-2015)的药房索赔数据,共纳入3005例65岁及以上2型糖尿病患者。

主要发现

  • 格列本脲使用率在各研究年度下降:2011年35.8%、2013年27.7%、2015年4.2%(P<.01)。
  • 2011年区域A和D使用格列本脲的调整比值比分别比总体平均低24%(P=.045)和11%(P<.01)。
  • 2013年区域A和D使用格列本脲的调整比值比分别比总体平均低37%(P<.01)和8%(P=.03),而区域B高41%(P=.04)。
  • 2015年无显著区域差异。
  • 2013年内科医生比家庭医学提供者使用格列本脲的比值比高47%(P<.01),其他研究年度无此差异。

临床怎么用

  • 老年2型糖尿病患者应避免使用格列本脲以降低低血糖风险,遵循AGS Beers Criteria建议。
  • 教育、系统层面举措和强有力的专业支持可能有助于更统一地采纳指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Glyburide was added to the 2012 American Geriatrics Society (AGS) Beers Criteria® due to the risk of hypoglycemic events in older adults. The objective of this study was to evaluate trends of glyburide use in persons aged 65 and older with diabetes mellitus, type II, before, during, and after the 2012 AGS Beers Criteria® Update. DESIGN: Multicenter retrospective cohort study comparing pharmacy claims data from four Sharp Rees-Stealy clinic regions over 5 years (2010-2015). SETTING: Pharmacy claims database. PARTICIPANTS: A total of 3,005 patients with diabetes mellitus, type II, aged 65 and older. MEASUREMENTS: Prescription fill history of the sulfonylureas glyburide, glipizide, and glimepiride were collected along with comorbidity (Elixhauser) and demographic information. Odds of glyburide prescribing were stratified by year, clinic region, and by prescriber type. RESULTS: Glyburide use decreased across each study year (35.8%, 27.7%, and 4.2% in 2011, 2013, and 2015, respectively; P < .01). Adjusted odds of glyburide use indicated that regions A and D were 24% (P = .045) and 11% (P < .01) less likely to prescribe glyburide in 2011, regions A and D were 37% (P < .01) and 8% (P = .03) less likely to prescribe glyburide in 2013, respective to the overall average, whereas region B was 41% (P = .04) more likely. No significant regional site variations remained in 2015. Internists were 47% more likely to prescribe glyburide than family medicine providers in 2013; P < .01), but not in any other study years. CONCLUSION: Rates of glyburide use decreased after release of the 2012 AGS Beers Criteria® demonstrating successful adoption of evidence-based medicine at a large multiregional site. However, regional differences may affect timing of implementation. Education, system-level initiatives, and strong professional support may help enhance more uniform adoption. J Am Geriatr Soc 68:2354-2358, 2020.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Herzik KA, Barnett MJ, Thanh DM, et al. Glyburide Use in Older Adults: Pharmacy Claims Data Analysis of a Regional Healthcare Organization. J Am Geriatr Soc. 2020. PMID: 32757475. doi:10.1111/jgs.16723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。